Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the appointment of Georges Gemayel (PhD) as chairman of its Board of Directors.

“I am very pleased to welcome Georges to Dynacure’s Board of Directors during this exciting stage in our company’s growth. His extensive experience will strengthen the team’s mission to transform the lives of patients and families affected by centronuclear myopathies (CNM),” said Stephane van Rooijen (CEO).

Dr. Gemayel has over 30 years of experience in the global biopharmaceutical industry: he was President and CEO of Altus Pharmaceuticals from 2008 to 2009; from 2003 to 2008 he was Executive Vice President at Genzyme Corporation where he was responsible for the company’s worldwide therapeutics businesses; and from 1988 to 2003 he held senior roles at Roche.

He currently serves as Chairman of the Board of Directors of Orphazyme, Oxthera and Enterome, and as Director of Momenta Pharmaceuticals and Supernus.

Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut, Lebanon, and earned a Ph.D. in pharmacology at Paris-Sud University in Paris, France.

“Dynacure’s scientific expertise and its compelling preclinical data will steer development of its up-coming clinical program in CNM”, said Georges Gemayel, “I’m thrilled to engage with the team to develop treatments for severe orphan disorders”.

Dynacure’s lead drug program, Dyn101, is an antisense oligonucleotide therapy in development for the rare and often fatal muscle diseasecentronuclear myopathy (CNM). Dyn101 is being developed in collaboration with Ionis Pharmaceuticals, the leading company in RNA-targeted drug discovery, development and commercialization.

About Dynacure: www.dynacure.com

Dynacure develops new treatments for patients suffering from serious orphan disorders. Dynacure’s lead program, Dyn101, is designed to address centronuclear myopathy (CNM), a rare and debilitating disease affecting children and young adults. The Dyn101 development program targets the Dynamin 2 protein using a cEt antisense oligonucleotide candidate developed in collaboration with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

Dynacure’s investors are Andera, Bpifrance, IdInvest, Kurma Partners and Pontifax.


NewCap – European Media Relations
Nicolas Merigeau
+33(0)1 44 71 94 98

Ten Bridge Communications – U.S. Media Relations
Tom Donovan
+1 857 559 3397

Stephane van Rooijen, CEO